<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Expert Opin Ther Pat</journal-id><journal-id journal-id-type="iso-abbrev">Expert Opin Ther Pat</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Expert opinion on therapeutic patents</journal-title></journal-title-group><issn pub-type="ppub">1354-3776</issn><issn pub-type="epub">1744-7674</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8957558</article-id><article-id pub-id-type="pmcid-ver">PMC8957558.1</article-id><article-id pub-id-type="pmcaid">8957558</article-id><article-id pub-id-type="pmcaiid">8957558</article-id><article-id pub-id-type="manuscript-id">NIHMS1771231</article-id><article-id pub-id-type="pmid">34991418</article-id><article-id pub-id-type="doi">10.1080/13543776.2022.2026926</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1771231</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1771231</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Factor IX(a) inhibitors: an updated patent review (2003-present)</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Afosah</surname><given-names initials="DK">Daniel K.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5675-1127</contrib-id><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ofori</surname><given-names initials="E">Edward</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4345-788X</contrib-id><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mottamal</surname><given-names initials="M">Madhusoodanan</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al-Horani</surname><given-names initials="RA">Rami A.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9146-2662</contrib-id><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Chemistry and Biochemistry, Washington and Lee University, Lexington VA 24450 USA</aff><aff id="A2"><label>2</label>Department of Pharmaceutical Sciences, College of Pharmacy, Chicago State University, Chicago, IL 60628 USA</aff><aff id="A3"><label>3</label>Department of Chemistry, College of Arts and Sciences, Xavier University of Louisiana, New Orleans, LA 70125, USA</aff><aff id="A4"><label>4</label>Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, Louisiana 70125 USA</aff><author-notes><corresp id="CR1">Corresponding author: Rami A. Al-Horani, 1 Drexel Drive, College of Pharmacy, New Orleans, LA 70125-1089, Phone: (504) 520-7603, Fax: (504) 520-7954, <email>ralhoran@xula.edu</email></corresp><fn fn-type="COI-statement" id="FN1"><p id="P52">Declaration of interests</p><p id="P53">The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>1</month><year>2022</year></pub-date><volume>32</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">404003</issue-id><fpage>381</fpage><lpage>400</lpage><pub-history><event event-type="nihms-submitted"><date><day>21</day><month>01</month><year>2022</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-13 05:25:22.640"><day>13</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1771231.pdf"/><abstract id="ABS1"><sec id="S1"><title>Introduction:</title><p id="P1">Anticoagulation with no bleeding complications is the current objective of drug discovery programs in the area of treating and/or preventing thromboembolism. Despite the promises of therapeutics targeting factors XI(a) and XII(a), none has been approved thus far. Clinically used thrombin- and/or factor Xa-based anticoagulants continue to be associated with a significant bleeding risk which limits their safe use in a broad range of thrombotic patients. Research findings in animals and humans indicate that it is possible to target factor IX(a) (FIX(a)) to achieve anticoagulation with a limited risk of bleeding.</p></sec><sec id="S2"><title>Areas covered:</title><p id="P2">A review of patents literature has retrieved &gt;35 patents on the development of molecules targeting FIX(a) since 2003. Small molecules, antibodies, and aptamers have been developed to target FIX(a) to potentially promote effective and safer anticoagulation. Most of these agents are in the pre-clinical development phase and few have been tested in clinical trials.</p></sec><sec id="S3"><title>Expert opinion:</title><p id="P3">FIX(a) system is being considered to develop new anticoagulants with fewer bleeding complications. Our survey indicates that the number of FIX(a)-targeting agents is mediocre. The agents under development are diverse. Although additional development is essential, moving one or more of these agents to the clinic will facilitate achieving better clinical outcomes.</p></sec></abstract><kwd-group><kwd>factor IX(a)</kwd><kwd>anticoagulants</kwd><kwd>small molecules</kwd><kwd>monoclonal antibodies</kwd><kwd>aptamers</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>